CCRCC
MCID: CLR030
MIFTS: 49

Clear Cell Renal Cell Carcinoma (CCRCC)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Clear Cell Renal Cell Carcinoma

MalaCards integrated aliases for Clear Cell Renal Cell Carcinoma:

Name: Clear Cell Renal Cell Carcinoma 12 53 59 15
Clear-Cell Metastatic Renal Cell Carcinoma 12 53 73
Clear Cell Carcinoma of Kidney 12 29 6
Conventional Renal Cell Carcinoma 12 73
Renal Clear Cell Carcinoma 12 55
Clear Cell Renal Cell Adenocarcinoma 59
Conventional Renal Cell Carcinoma 12
Clear Cell Kidney Carcinoma 12
Cystic-Multilocular Variant 53
Clear Cell Renal Carcinoma 59
Clear Cell Rcc 53
Ccrcc 59

Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:4467
MeSH 44 D002292
NCIt 50 C4033
SNOMED-CT 68 41607009
Orphanet 59 ORPHA319276
UMLS via Orphanet 74 C0279702
ICD10 via Orphanet 34 C64

Summaries for Clear Cell Renal Cell Carcinoma

NIH Rare Diseases : 53 Clear cell renal cell carcinoma is a cancer of the kidney.  The name "clear cell" refers to the appearance of the cancer cells when viewed with a microscope.  Clear cell renal cell carcinoma occurs when cells in the kidney quickly increase in number, creating a lump (mass).  Though the exact cause of clear cell renal cell carcinoma is unknown, smoking, the excessive use of certain medications, and several genetic predisposition conditions (such as von Hippel Lindau syndrome) may contribute to the development of this type of cancer.  Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.

MalaCards based summary : Clear Cell Renal Cell Carcinoma, also known as clear-cell metastatic renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Clear Cell Renal Cell Carcinoma is PBRM1 (Polybromo 1). The drugs Aldesleukin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells.

Disease Ontology : 12 A renal cell carcinoma that has material basis in cells that appear very pale or clear when examined under microscope.

Wikipedia : 76 The Clear Cell Renal Cell Carcinoma (CCRCC) is a type of renal cell... more...

Related Diseases for Clear Cell Renal Cell Carcinoma

Diseases related to Clear Cell Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 33.5 CYTOR HNF1A LINC00887 MALAT1 OGG1 PANDAR
2 clear cell papillary renal cell carcinoma 30.8 HNF1A PBRM1
3 kidney cancer 30.6 MALAT1 MEG3 PVT1
4 intrahepatic cholangiocarcinoma 30.3 CCAT2 PBRM1 TUG1
5 thyroid cancer, nonmedullary, 1 30.2 MALAT1 MEG3 PVT1
6 cholangiocarcinoma 30.1 CCAT2 MALAT1 OGG1 PANDAR SPRY4-IT1 TUG1
7 myeloma, multiple 30.1 MALAT1 MEG3 PVT1 TUG1
8 melanoma 29.8 MALAT1 MEG3 PVT1 SPRY4-IT1
9 lung cancer 29.6 ADAMTS9-AS2 CCAT2 DGCR5 LUCAT1 MALAT1 MEG3
10 breast cancer 29.6 CCAT2 CYTOR MALAT1 MEG3 NBAT1 PANDAR
11 multilocular clear cell renal cell carcinoma 12.5
12 hereditary conventional renal cell carcinoma 12.4
13 multilocular cystic renal neoplasm of low malignant potential 11.7
14 chromophobe renal cell carcinoma 11.6
15 birt-hogg-dube syndrome 11.2
16 von hippel-lindau syndrome 11.2
17 renal cell carcinoma, xp11-associated 11.2
18 hypoxia 10.6
19 angiomyolipoma 10.4
20 renal cell carcinoma, papillary, 1 10.4
21 hemangioblastoma 10.4
22 oncocytoma 10.3
23 ovarian epithelial cancer 10.2 MALAT1 MEG3
24 pituitary adenoma 10.2 CCAT2 MALAT1 MEG3
25 microvascular complications of diabetes 3 10.2 MALAT1 PVT1
26 vulva squamous cell carcinoma 10.2 MALAT1 MEG3
27 malignant glioma 10.2 CYTOR PVT1 SPRY4-IT1 TUG1
28 squamous cell carcinoma 10.2 CCAT2 MALAT1 SPRY4-IT1 TUG1
29 tongue squamous cell carcinoma 10.2 CYTOR MALAT1 MEG3
30 insulin-like growth factor i 10.2
31 body mass index quantitative trait locus 1 10.2
32 renal oncocytoma 10.2
33 adenocarcinoma 10.2
34 chromophil renal cell carcinoma 10.2
35 testicular germ cell cancer 10.2 MEG3 SPRY4-IT1
36 small cell cancer of the lung 10.2 CCAT2 MALAT1 TUG1
37 oral squamous cell carcinoma 10.1 CCAT2 MALAT1 MEG3 TUG1
38 bladder urothelial carcinoma 10.1 MALAT1 MEG3 PVT1 TUG1
39 gallbladder cancer 10.1 CYTOR MALAT1 MEG3 TUG1
40 lung squamous cell carcinoma 10.1 CCAT2 MEG3 PVT1 TUG1
41 esophageal cancer 10.1 CYTOR LUCAT1 MALAT1 MEG3 PVT1
42 hemangioma 10.1
43 hepatitis 10.1
44 hepatitis a 10.1
45 adenoma 10.1
46 kidney angiomyolipoma 10.1
47 b-cell lymphomas 10.1 MALAT1 PVT1 TUG1
48 glioma 10.1 CCAT2 CYTOR LUCAT1 MALAT1 MEG3 PVT1
49 osteogenic sarcoma 10.0 CCAT2 LUCAT1 MALAT1 MEG3 PANDAR PVT1
50 glioblastoma 10.0 CYTOR DGCR5 MALAT1 MEG3 TUG1

Graphical network of the top 20 diseases related to Clear Cell Renal Cell Carcinoma:



Diseases related to Clear Cell Renal Cell Carcinoma

Symptoms & Phenotypes for Clear Cell Renal Cell Carcinoma

UMLS symptoms related to Clear Cell Renal Cell Carcinoma:


flank pain

Drugs & Therapeutics for Clear Cell Renal Cell Carcinoma

Drugs for Clear Cell Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
2
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
3
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
4
Nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 946414-94-4
5 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
6 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
9 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
10 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
16 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
20
Everolimus Approved Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
21
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24
Axitinib Approved, Investigational Phase 3,Phase 2,Phase 1 319460-85-0 6450551
25 Interferon-alpha Phase 3,Phase 2,Phase 1
26 interferons Phase 3,Phase 2,Phase 1
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
31 Micronutrients Phase 3,Phase 1,Phase 2,Not Applicable
32 Anti-Infective Agents, Local Phase 3
33 cadexomer iodine Phase 3
34 Trace Elements Phase 3,Phase 1,Phase 2,Not Applicable
35 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
37 tyrosine Phase 3,Phase 1,Phase 2
38 Immunoglobulin G Phase 3,Phase 2,Phase 1,Early Phase 1
39 Endothelial Growth Factors Phase 3,Phase 2,Phase 1,Early Phase 1
40 Mitogens Phase 3,Phase 2,Phase 1,Early Phase 1
41 Immunoconjugates Phase 3,Phase 1
42
Tinzaparin Approved Phase 1, Phase 2 9005-49-6, 9041-08-1 25244225
43
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 46507594
44
Dalteparin Approved Phase 1, Phase 2 9005-49-6
45
Panobinostat Approved, Investigational Phase 2,Phase 1 404950-80-7 6918837
46
leucovorin Approved Phase 2 58-05-9 6006 143
47
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
48
Nicotinamide Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 98-92-0 936
49
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
50
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311

Interventional clinical trials:

(show top 50) (show all 218)
# Name Status NCT ID Phase Drugs
1 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
2 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
3 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
4 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
5 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
6 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
7 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
8 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
9 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
10 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
11 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
12 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
13 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
14 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
15 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
16 Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Not yet recruiting NCT03793166 Phase 3 Cabozantinib
17 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated NCT01599754 Phase 3 Axitinib;Placebo
18 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Terminated NCT01198158 Phase 3 Everolimus
19 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
20 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
21 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
22 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
23 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
24 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
25 Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC) Unknown status NCT01731158 Phase 2 Avastin in combination with Roferon-A;Afinitor;Sutent, Nexavar or Votrient
26 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
27 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
28 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
29 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
30 Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Completed NCT02923531 Phase 1, Phase 2 X4P-001;Nivolumab
31 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
32 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
33 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
34 Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer Completed NCT02002312 Phase 2 Lu-177-DOTA-girentuximab
35 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer Completed NCT00408902 Phase 2 tandutinib
36 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
37 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed NCT00193258 Phase 1, Phase 2 Bevacizumab;Erlotinib;Imatinib
38 Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Completed NCT00323739 Phase 2 bevacizumab;RAD001
39 Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus Completed NCT01715935 Phase 2 Everolimus
40 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
41 Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer Completed NCT00278174 Phase 2
42 Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Completed NCT00392821 Phase 1, Phase 2 Sorafenib;RAD001
43 Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01158222 Phase 2 sunitinib malate
44 Rotating Pazopanib and Everolimus to Avoid Resistance Completed NCT01408004 Phase 2 Pazopanib;Everolimus;Pazopanib;Everolimus;Everolimus;Pazopanib
45 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease Completed NCT00523159 Phase 2 Endoxana, IMA901, Leukine;IMA901 and Leukine
46 Bryostatin 1 In Treating Patients With Progressive Kidney Cancer Completed NCT00005056 Phase 2 bryostatin 1
47 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
48 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy Completed NCT01141569 Phase 2 Gamma-Secretase Inhibitor RO4929097
49 Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer Completed NCT01024205 Phase 2 sunitinib malate
50 Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Completed NCT00378703 Phase 2 Sorafenib Tosylate;Temsirolimus

Search NIH Clinical Center for Clear Cell Renal Cell Carcinoma

Genetic Tests for Clear Cell Renal Cell Carcinoma

Genetic tests related to Clear Cell Renal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Clear Cell Carcinoma of Kidney 29

Anatomical Context for Clear Cell Renal Cell Carcinoma

MalaCards organs/tissues related to Clear Cell Renal Cell Carcinoma:

41
Kidney, Endothelial, T Cells, Lung, Bone, Brain, Thyroid

Publications for Clear Cell Renal Cell Carcinoma

Articles related to Clear Cell Renal Cell Carcinoma:

(show top 50) (show all 1606)
# Title Authors Year
1
Successful partial nephrectomy of a T1b multilocular clear cell renal cell carcinoma arising in a renal graft. ( 30345224 )
2019
2
Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. ( 30365137 )
2019
3
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. ( 30183478 )
2019
4
Phosphoinositide-dependent kinase 1-associated glycolysis is regulated by miR-409-3p in clear cell renal cell carcinoma. ( 30218446 )
2019
5
Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. ( 29974846 )
2018
6
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. ( 29396852 )
2018
7
Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma. ( 29963157 )
2018
8
Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. ( 29350403 )
2018
9
Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. ( 29946925 )
2018
10
Genetic and metabolic hallmarks of clear cell renal cell carcinoma. ( 29959988 )
2018
11
SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-I_B signaling. ( 29183723 )
2018
12
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. ( 29357836 )
2018
13
Leukemia Inhibitory Factor Receptor Suppresses the Metastasis of Clear Cell Renal Cell Carcinoma Through Negative Regulation of the Yes-Associated Protein. ( 29902078 )
2018
14
FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. ( 29368368 )
2018
15
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. ( 29368125 )
2018
16
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma. ( 29944950 )
2018
17
DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NFa89I_B pathway. ( 29901172 )
2018
18
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. ( 29910061 )
2018
19
Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma. ( 29935195 )
2018
20
Long noncoding RNA lung cancer associated transcript 1 promotes proliferation and invasion of clear cell renal cell carcinoma cells by negatively regulating miR-495-3p. ( 29932248 )
2018
21
Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma. ( 29426696 )
2018
22
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. ( 29378660 )
2018
23
Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma. ( 29374850 )
2018
24
Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. ( 29192325 )
2018
25
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus. ( 29903415 )
2018
26
Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. ( 29290798 )
2018
27
MicroRNA-19a and microRNA-19b promote the malignancy of clear cell renal cell carcinoma through targeting the tumor suppressor RhoB. ( 29474434 )
2018
28
Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling. ( 29968912 )
2018
29
p53I^: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median followup. ( 29346503 )
2018
30
PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival. ( 29169846 )
2018
31
Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. ( 29500651 )
2018
32
Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. ( 29433989 )
2018
33
PPARI^ is dispensable for clear cell renal cell carcinoma progression. ( 29866440 )
2018
34
Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems. ( 29356723 )
2018
35
Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. ( 29967134 )
2018
36
The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. ( 29872221 )
2018
37
Decreased Expression of SATB2 Associates with Tumor Growth and Predicts Worse Outcome in Patients with Clear Cell Renal Cell Carcinoma. ( 29374710 )
2018
38
Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. ( 29357946 )
2018
39
Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. ( 29973214 )
2018
40
The prognostic significance of nuclear expression of PHF2 and C/EBPI+ in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution. ( 29416602 )
2018
41
Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. ( 29949668 )
2018
42
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. ( 29967214 )
2018
43
MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1. ( 29394133 )
2018
44
Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma. ( 29434939 )
2018
45
Tumor-to-Tumor Metastasis - a Unique Case of Clear Cell Renal Cell Carcinoma Harboring Metastasis of Adenocarcinoma of Unknown Origin. ( 30541323 )
2018
46
Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Differentiation of Minimal Fat Angiomyolipoma from Clear Cell Renal Cell Carcinoma. ( 30087067 )
2018
47
Three Primary Carcinomas on 18F-FDG PET/CT: Intrahepatic Cholangiocarcinoma, Papillary Renal Cell Carcinoma, and Clear Cell Renal Cell Carcinoma. ( 29561526 )
2018
48
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. ( 30275199 )
2018
49
Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model. ( 30277889 )
2018
50
Construction and comprehensive analysis of dysregulated long non-coding RNA-associated competing endogenous RNA network in clear cell renal cell carcinoma. ( 30278113 )
2018

Variations for Clear Cell Renal Cell Carcinoma

ClinVar genetic disease variations for Clear Cell Renal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh37 Chromosome 3, 9792107: 9792107
2 OGG1 NM_016828.2(OGG1): c.137G> A (p.Arg46Gln) single nucleotide variant Pathogenic rs104893751 GRCh38 Chromosome 3, 9750423: 9750423
3 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh37 Chromosome 12, 121432125: 121432125
4 HNF1A NM_000545.6(HNF1A): c.872dupC (p.Gly292Argfs) duplication Pathogenic rs587776825 GRCh38 Chromosome 12, 120994322: 120994322
5 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Uncertain significance rs137853247 GRCh37 Chromosome 12, 121416663: 121416663
6 HNF1A NM_000545.6(HNF1A): c.92G> A (p.Gly31Asp) single nucleotide variant Uncertain significance rs137853247 GRCh38 Chromosome 12, 120978860: 120978860
7 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh37 Chromosome 3, 52597380: 52597387
8 PBRM1 NM_018313.4(PBRM1): c.3923_3930delATAGTGAG (p.Asp1308Valfs) deletion Pathogenic rs864321679 GRCh38 Chromosome 3, 52563364: 52563371

Cosmic variations for Clear Cell Renal Cell Carcinoma:

9 (show top 50) (show all 2131)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 32
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 32
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 32
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 32
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 32
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 32
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 32
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 32
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 32
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 32
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 32
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 32
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 32
14 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 31
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 31
16 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 31
17 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 31
18 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 31
19 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 31
20 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 31
21 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 31
22 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 31
23 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 31
24 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 31
25 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 31
26 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 31
27 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 31
28 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 31
29 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 31
30 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 31
31 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 31
32 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 31
33 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 31
34 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 31
35 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 31
36 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 31
37 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 31
38 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 31
39 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 31
40 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 31
41 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 31
42 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 31
43 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 31
44 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 31
45 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 31
46 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 31
47 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 31
48 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 31
49 COSM6921803 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.3493T>C p.F1165L 12:18562728-18562728 31
50 COSM6922195 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.1986G>C p.Q662H 12:18391235-18391235 31

Copy number variations for Clear Cell Renal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 135083 2 111395408 111435684 Copy number BUB1 Clear cell renal cell carcinoma
2 181389 4 120800000 123800000 Copy number MAD2L1 Clear cell renal cell carcinoma

Expression for Clear Cell Renal Cell Carcinoma

Search GEO for disease gene expression data for Clear Cell Renal Cell Carcinoma.

Pathways for Clear Cell Renal Cell Carcinoma

GO Terms for Clear Cell Renal Cell Carcinoma

Sources for Clear Cell Renal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....